These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16029149)

  • 1. Anti-HIV activities of natural antioxidant caffeic acid derivatives: toward an antiviral supplementation diet.
    Bailly F; Cotelle P
    Curr Med Chem; 2005; 12(15):1811-8. PubMed ID: 16029149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporation of Privileged Structures into Bevirimat Can Improve Activity against Wild-Type and Bevirimat-Resistant HIV-1.
    Zhao Y; Gu Q; Morris-Natschke SL; Chen CH; Lee KH
    J Med Chem; 2016 Oct; 59(19):9262-9268. PubMed ID: 27676157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, anti-HIV and anti-oxidant activities of caffeoyl 5,6-anhydroquinic acid derivatives.
    Ma CM; Kawahata T; Hattori M; Otake T; Wang L; Daneshtalab M
    Bioorg Med Chem; 2010 Jan; 18(2):863-9. PubMed ID: 20004585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationships: analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication.
    King PJ; Ma G; Miao W; Jia Q; McDougall BR; Reinecke MG; Cornell C; Kuan J; Kim TR; Robinson WE
    J Med Chem; 1999 Feb; 42(3):497-509. PubMed ID: 9986720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to win the HIV-1 drug resistance hurdle race: running faster or jumping higher?
    Garbelli A; Riva V; Crespan E; Maga G
    Biochem J; 2017 Apr; 474(10):1559-1577. PubMed ID: 28446620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters.
    Pluymers W; Neamati N; Pannecouque C; Fikkert V; Marchand C; Burke TR; Pommier Y; Schols D; De Clercq E; Debyser Z; Witvrouw M
    Mol Pharmacol; 2000 Sep; 58(3):641-8. PubMed ID: 10953059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chicoric acid analogues as HIV-1 integrase inhibitors.
    Lin Z; Neamati N; Zhao H; Kiryu Y; Turpin JA; Aberham C; Strebel K; Kohn K; Witvrouw M; Pannecouque C; Debyser Z; De Clercq E; Rice WG; Pommier Y; Burke TR
    J Med Chem; 1999 Apr; 42(8):1401-14. PubMed ID: 10212126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of caffeoyl-anilides as portmanteau inhibitors of HIV-1 integrase and CCR5.
    Bodiwala HS; Sabde S; Gupta P; Mukherjee R; Kumar R; Garg P; Bhutani KK; Mitra D; Singh IP
    Bioorg Med Chem; 2011 Feb; 19(3):1256-63. PubMed ID: 21227704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral drugs that target cellular proteins may play major roles in combating HIV resistance.
    Provencher VM; Coccaro E; Lacasse JJ; Schang LM
    Curr Pharm Des; 2004; 10(32):4081-101. PubMed ID: 15579090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of Current Cell-Penetrating Antibody Developments for HIV-1 Therapy.
    Che Nordin MA; Teow SY
    Molecules; 2018 Feb; 23(2):. PubMed ID: 29415435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-AIDS agents, 18. Sodium and potassium salts of caffeic acid tetramers from Arnebia euchroma as anti-HIV agents.
    Kashiwada Y; Nishizawa M; Yamagishi T; Tanaka T; Nonaka G; Cosentino LM; Snider JV; Lee K
    J Nat Prod; 1995 Mar; 58(3):392-400. PubMed ID: 7775984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of CAPE-like compounds on HIV replication in vitro and modulation of cytokines in vivo.
    Ho CC; Lin SS; Chou MY; Chen FL; Hu CC; Chen CS; Lu GY; Yang CC
    J Antimicrob Chemother; 2005 Aug; 56(2):372-9. PubMed ID: 16002419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caffeic Acid, a versatile pharmacophore: an overview.
    Touaibia M; Jean-François J; Doiron J
    Mini Rev Med Chem; 2011 Jul; 11(8):695-713. PubMed ID: 21679136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemistry and biological activities of caffeic acid derivatives from Salvia miltiorrhiza.
    Jiang RW; Lau KM; Hon PM; Mak TC; Woo KS; Fung KP
    Curr Med Chem; 2005; 12(2):237-46. PubMed ID: 15638738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targets for inhibition of HIV replication: entry, enzyme action, release and maturation.
    Sierra-Aragón S; Walter H
    Intervirology; 2012; 55(2):84-97. PubMed ID: 22286875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-Activity-Relationship and Mechanistic Insights for Anti-HIV Natural Products.
    Kaur R; Sharma P; Gupta GK; Ntie-Kang F; Kumar D
    Molecules; 2020 Apr; 25(9):. PubMed ID: 32365518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-HIV drug development--an overview.
    Pereira CF; Paridaen JT
    Curr Pharm Des; 2004; 10(32):4005-37. PubMed ID: 15579085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In search of authentic inhibitors of HIV-1 integration.
    Debyser Z; Cherepanov P; Van Maele B; De Clercq E; Witvrouw M
    Antivir Chem Chemother; 2002 Jan; 13(1):1-15. PubMed ID: 12180645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment interruptions in HIV-infected subjects.
    Bongiovanni M; Casana M; Tincati C; d'Arminio Monforte A
    J Antimicrob Chemother; 2006 Sep; 58(3):502-5. PubMed ID: 16816398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.